Interventions in Acute or Subacute Phase for Type B Aortic Dissection.

IF 0.6 Q4 PERIPHERAL VASCULAR DISEASE
Annals of vascular diseases Pub Date : 2024-06-25 Epub Date: 2024-03-26 DOI:10.3400/avd.ra.24-00012
Masaaki Kato
{"title":"Interventions in Acute or Subacute Phase for Type B Aortic Dissection.","authors":"Masaaki Kato","doi":"10.3400/avd.ra.24-00012","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment strategy for acute and subacute Stanford type B aortic dissection has changed significantly since the advent of thoracic endovascular aortic repair (TEVAR). Indication for invasive treatment: In addition to the conventional complicated cases (rupture or malperfusion case), the indication for invasive treatment now includes cases with refractory hypertension, persistent or recurrent pain, large aortic diameter, and other conditions that are considered to have a poor prognosis with conservative treatment. Treatment methods: TEVAR is the first choice for acute, subacute, and early chronic-stage treatment, and when this is not possible, other techniques (fenestration and graft replacement) are chosen. Treatment timing: The timing of invasive treatment should be emergent in life-threatening conditions (for rupture or malperfusion case) and immediate in symptomatic cases, while in other cases, preemptive TEVAR is considered appropriate on a scheduled timing within 6 months of onset. (This is a translation of Jpn J Vasc Surg 2023; 32: 157-163.).</p>","PeriodicalId":7995,"journal":{"name":"Annals of vascular diseases","volume":"17 2","pages":"120-127"},"PeriodicalIF":0.6000,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11196166/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of vascular diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3400/avd.ra.24-00012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/26 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0

Abstract

The treatment strategy for acute and subacute Stanford type B aortic dissection has changed significantly since the advent of thoracic endovascular aortic repair (TEVAR). Indication for invasive treatment: In addition to the conventional complicated cases (rupture or malperfusion case), the indication for invasive treatment now includes cases with refractory hypertension, persistent or recurrent pain, large aortic diameter, and other conditions that are considered to have a poor prognosis with conservative treatment. Treatment methods: TEVAR is the first choice for acute, subacute, and early chronic-stage treatment, and when this is not possible, other techniques (fenestration and graft replacement) are chosen. Treatment timing: The timing of invasive treatment should be emergent in life-threatening conditions (for rupture or malperfusion case) and immediate in symptomatic cases, while in other cases, preemptive TEVAR is considered appropriate on a scheduled timing within 6 months of onset. (This is a translation of Jpn J Vasc Surg 2023; 32: 157-163.).

B 型主动脉夹层急性期或亚急性期的干预措施。
自从胸腔内主动脉血管修复术(TEVAR)问世以来,急性和亚急性斯坦福B型主动脉夹层的治疗策略发生了重大变化。有创治疗的适应症:除了传统的复杂病例(破裂或灌注不良病例)外,现在有创治疗的适应症还包括难治性高血压、持续或反复疼痛、主动脉直径过大以及其他保守治疗预后不良的病例。治疗方法:TEVAR 是急性期、亚急性期和早期慢性期治疗的首选,如果无法进行 TEVAR 治疗,则选择其他技术(瓣膜置换术和移植物置换术)。治疗时机:对于危及生命的病例(破裂或灌注不良病例),应立即进行有创治疗;对于无症状病例,应立即进行有创治疗;而对于其他病例,则应在发病后 6 个月内按计划进行先期 TEVAR。(本文译自《Jpn J Vasc Surg 2023; 32: 157-163》)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of vascular diseases
Annals of vascular diseases PERIPHERAL VASCULAR DISEASE-
自引率
0.00%
发文量
41
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信